Veeva Systems Inc. · NYSE:VEEV
Veeva Systems — J.P. Morgan Healthcare Conference 2026
21 slides from Veeva Systems's conference presentation, Jan 13, 2026
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference January 13, 2026
Slide 2: Brian Van Wagener, Chief Financial Officer
Brian Van Wagener Chief Financial Officer
Slide 3: Safe Harbor and Other Information
Safe Harbor and Other Information This presentation and associated commentary contain forward-looking statements regarding Veeva’s future plans and expected performance, market size and opportunity, and financial outlook, including guidance provided as of November 20, 2025, about Veeva’s expected fu
Slide 4: Vision and Values
Vision Building the Industry Cloud for Life Sciences Values Do the Right Thing Customer Success Employee Success Speed A Public Benefit Corporation
Slide 5: The Industry Cloud for Life Sciences
The Industry Cloud for Life Sciences Software • Data • Business Consulting Development Quality Commercial Data Cloud Cloud Cloud Cloud Business Consulting
Slide 6: Our Structural Advantage
Our Structural Advantage Suite Critical Systems Product Effect Systems of Record Excellence
Slide 7: Execution Across a Broad Portfolio
Execution Across a Broad Portfolio Unique Operating Model Focused Teams and Leadership Product Excellence | Customer Success | Reference Selling
Slide 8: Time of Change for Life Sciences
Time of Change for Life Sciences AI moving to the Connected Evolving R&D productivity forefront ecosystem commercial is essential models
Slide 9: Veeva is Innovating and Executing
Veeva is Innovating and Executing Innovation in Innovation for Veeva AI the Product the Industry
Slide 10: Veeva CRM Migrating to Vault
Veeva CRM Migrating to Vault • Main competition is Salesforce • Expect to remain the clear market leader • New sales and migration projects going well • 115+ customers live including top 20s • Focus is customer success, innovation, AI
Slide 11: CRM in Perspective
CRM was our first product in 2007 ~75% of Veeva revenue in 2015 CRM in ~20% of Veeva revenue in 2025 Perspective ~10% of Veeva revenue in 2030 Expect to remain the clear market leader
Slide 12: On Track for Our 2030 Goal
On Track for Our 2030 Goal MedTech ~5% Regulatory & Safety ~11% Quality ~19% MedTech ~5% Clinical ~30% Regulatory & Safety ~12% Quality ~17% Clinical ~21% Commercial ~35% Commercial ~45% Today 2030 Today reflects annualized Q3’26 subscription revenue. 2030 reflects estimated CY30 run rate subscripti
Slide 13: Consistent History of Growth and Profitability
Consistent History of Growth and Profitability $3.17B Revenue $2.75B Non-GAAP Operating Income1 $2.36B $2.16B $1.85B $1.47B $1.42B $1.15B $830M $843M $759M $583M FY212 FY22 FY23 FY243 FY25 FY26E4 Fiscal Year Ending January 31 ¹ A reconciliation of GAAP to non-GAAP measures is set forth in the Append
Slide 14: Investment Concentrated in Product
Investment Concentrated in Product Sales & Product Excellence Marketing 24% Product Supporting Customer Success Functions 66% 10% Reference Selling Represents Q3’26 mix of total non-GAAP subscription expenses. Total Non-GAAP subscription expense = Product expense + Sales & Marketing expense + Suppor
Slide 15: Capital Allocation Priorities
Capital Allocation Priorities 2030 Goal, Veeva AI, Cross-Industry Disciplined Approach to Acquisitions Share Repurchase Program
Slide 16: Veeva Highlights
Veeva Highlights • Building the industry cloud for life sciences • Broad portfolio of mission-critical products • Strong growth and profitability for the long term • Continued focus on innovation, customer success and product excellence
Slide 17: Q&A
Veeva Q&A
Slide 18: Appendix
Veeva Appendix
Slide 19: Statement Regarding Use of Non-GAAP Financial Measures
Statement Regarding Use of Non-GAAP Financial Measures We provide the following non-GAAP measures, which we define as financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP: Non-GAAP gross margin, non-GAAP operating
Slide 20: Reconciliation of GAAP to Non-GAAP Measures
Reconciliation of GAAP to Non-GAAP Measures in millions FY'21 FY'22 FY'23 FY'24 FY'25 Operating income on a GAAP basis $ 377.8 $ 505.5 $ 459.1 $ 429.3 $ 691.4 Stock-based compensation expense 185.0 234.6 351.9 393.7 437.4 Amortization of purchased intangibles 20.0 18.5 19.5 19.5 18.6 Litigation sett
Slide 21: Reconciliation of GAAP to Non-GAAP Measures
Reconciliation of GAAP to Non-GAAP Measures Q3'26 Cost of subscription services revenues on a GAAP basis $ 94.2 Stock-based compensation expense (1.8) Amortization of purchased intangibles (1.0) Cost of subscription services revenues on a non-GAAP basis $ 91.3 Q3'26 Research and development expense
Veeva Systems — J.P. Morgan Healthcare Conference 2026 on 6ix